Insmed reported $409.75M in Cash and Equivalent for its first fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acelrx Pharmaceuticals ACRX:US $ 34.36M 7.09M
Alexion Pharmaceuticals ALXN:US $ 3429.6M 465.1M
Alimera Sciences ALIM:US $ 8.27M 2.94M
Arena Pharmaceuticals ARNA:US $ 432.98M 213.43M
Biomarin Pharmaceutical BMRN:US $ 641.53M 25.78M
Cytokinetics CYTK:US $ 425.58M 342.59M
Dynavax Technologies DVAX:US $ 79.06M 46.98M
Flexion Therapeutics FLXN:US $ 98.71M 9M
Gilead Sciences GILD:US $ 4065M 1932M
Heron Therapeutics HRTX:US $ 59.74M 45.4M
Insmed INSM:US $ 409.75M 123M
Mirati Therapeutics MRTX:US $ 294.89M 570.28M
Novartis NVS:US $ 5117M 1316M
Regeneron Pharmaceuticals REGN:US $ 1437.9M 755.8M
Sarepta Therapeutics SRPT:US $ 1481.84M 20.81M
Seattle Genetics SGEN:US $ 373.71M 184.71M
Ultragenyx Pharmaceutical RARE:US $ 383.79M 329.73M
Vertex Pharmaceuticals VRTX:US $ 6304.33M 316.14M